Description
Gabapentin-d
4 is intended for use as an internal standard for the quantification of gabapentin by GC- or LC-MS. Gabapentin is a γ-aminobutyric acid (GABA) analogue that acts as an anticonvulsant. It does not bind to GABA receptors, does not influence neural uptake of GABA, and does not inhibit the GABA-metabolizing enzyme, GABA transaminase. Unlike GABA, which does not pass through the blood-brain barrier, gabapentin penetrates into the central nervous system and binds to the α
2δ-type voltage-gated calcium channels. Formulations containing gabapentin have been used to treat neuropathic pain caused by complex regional pain syndrome type one, cancer, and HIV as well as to control dysesthesias in patients with multiple sclerosis.
References
[1] ANTON C VAN DE VUSSE. Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379].[J]. BMC Neurology, 2004, 4: 13. DOI:
10.1186/1471-2377-4-13[2] K HAHN. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies.[J]. Journal of Neurology, 2004, 251 10: 1260-1266. DOI:
10.1007/s00415-004-0529-6[3] LUU M. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the gabapentin cancer pain study group[J]. Douleurs, 2005, 6 1: Pages 49-50. DOI:
10.1016/s1624-5687(05)80227-6[4] N S GEE. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel.[J]. The Journal of Biological Chemistry, 1996, 271 10: 5768-5776. DOI:
10.1074/jbc.271.10.5768[5] KAREN L GOA Eugene M S. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy.[J]. Drugs, 1993, 46 3: 409-427. DOI:
10.2165/00003495-199346030-00007
